madman
Super Moderator
* Starting today, providers will be able to prescribe tailored doses of compounded enclomiphene4 through the Hims & Hers platform and, for men experiencing sexual symptoms, offer personalized testosterone care that combines enclomiphene with tadalafil in a single dual-action treatment.
* Starting in 2026, that will include an exclusive branded oral testosterone (KYZATREX®) through a major health platform exclusive collaboration with Marius Pharmaceuticals.
news.hims.com
An estimated twenty million men in the US struggle with low testosterone.1 2 The American Urology Association recommends testosterone therapy for men presenting symptoms3 in order to help with changes in energy, mood, and sexual desire. However, most never get help. Why? Stigma, outdated treatments, and costs that put care out of reach.
That ends today.
We’re opening up a new era in low testosterone care, with a range of treatment plans designed to be personal, accessible, and affordable. Starting in 2026, that will include an exclusive branded oral testosterone (KYZATREX®) through a major health platform exclusive collaboration with Marius Pharmaceuticals.
Starting today, providers will be able to prescribe tailored doses of compounded enclomiphene4 through the Hims & Hers platform and, for men experiencing sexual symptoms, offer personalized testosterone care that combines enclomiphene with tadalafil in a single dual-action treatment. Enclomiphene restores natural testosterone production, without compromising fertility, and has been shown to double testosterone levels.5 Customers begin with a simple at-home blood test, get results in days instead of months, and then work with their provider to find the best treatment plan, if eligible.
Next year, we’re expanding into testosterone treatment, including the launch of an exclusive branded oral testosterone through a major health platform exclusive collaboration with Marius Pharmaceuticals, a leader in testosterone therapy innovation. KYZATREX® is a needle-free FDA-approved oral TRT shown to restore testosterone levels in up to 96% of men.6 On average, it doubles free testosterone, the kind of testosterone associated with energy, drive, and performance.7 We also expect to introduce an injectable testosterone offering in 2026 to give men even more choice, all connected through our digital platform, with licensed providers and 24/7 access to care. We’re increasing access to leading-edge treatments to our platform, at a price point designed for everyone.
This is only the start for a specialty we plan to keep expanding. Our focus is on providing access to clinically rigorous, personalized care that evolves with the needs of each man who comes to us looking for support. This isn’t just about one product. It’s about building a new model of care. Transparent, accessible, and always on.
Low testosterone treatment has been stuck in the past. We’re moving it forward, and making it available to millions.
* Starting in 2026, that will include an exclusive branded oral testosterone (KYZATREX®) through a major health platform exclusive collaboration with Marius Pharmaceuticals.
The New Standard in Testosterone Treatment: Exclusive Branded Oral Testosterone and Expanded Treatment Options
We’re opening up a new era in low testosterone care, with a range of treatment plans designed to be personal, accessible, and affordable.
news.hims.com
An estimated twenty million men in the US struggle with low testosterone.1 2 The American Urology Association recommends testosterone therapy for men presenting symptoms3 in order to help with changes in energy, mood, and sexual desire. However, most never get help. Why? Stigma, outdated treatments, and costs that put care out of reach.
That ends today.
We’re opening up a new era in low testosterone care, with a range of treatment plans designed to be personal, accessible, and affordable. Starting in 2026, that will include an exclusive branded oral testosterone (KYZATREX®) through a major health platform exclusive collaboration with Marius Pharmaceuticals.
Starting today, providers will be able to prescribe tailored doses of compounded enclomiphene4 through the Hims & Hers platform and, for men experiencing sexual symptoms, offer personalized testosterone care that combines enclomiphene with tadalafil in a single dual-action treatment. Enclomiphene restores natural testosterone production, without compromising fertility, and has been shown to double testosterone levels.5 Customers begin with a simple at-home blood test, get results in days instead of months, and then work with their provider to find the best treatment plan, if eligible.
Next year, we’re expanding into testosterone treatment, including the launch of an exclusive branded oral testosterone through a major health platform exclusive collaboration with Marius Pharmaceuticals, a leader in testosterone therapy innovation. KYZATREX® is a needle-free FDA-approved oral TRT shown to restore testosterone levels in up to 96% of men.6 On average, it doubles free testosterone, the kind of testosterone associated with energy, drive, and performance.7 We also expect to introduce an injectable testosterone offering in 2026 to give men even more choice, all connected through our digital platform, with licensed providers and 24/7 access to care. We’re increasing access to leading-edge treatments to our platform, at a price point designed for everyone.
This is only the start for a specialty we plan to keep expanding. Our focus is on providing access to clinically rigorous, personalized care that evolves with the needs of each man who comes to us looking for support. This isn’t just about one product. It’s about building a new model of care. Transparent, accessible, and always on.
Low testosterone treatment has been stuck in the past. We’re moving it forward, and making it available to millions.
